Search
PF-03882845
go.drugbank.com/drugs/DB11814InvestigationalPF-03882845 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 and Type 2 Diabetic Nephropathy.
Tomivosertib
go.drugbank.com/drugs/DB15219InvestigationalTomivosertib is under investigation in clinical trial NCT03318562 (A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC).
Adenine
go.drugbank.com/drugs/DB00173ApprovedInvestigationalNutraceuticalA purine base and a fundamental unit of adenine nucleotides.
Mixtures: CPD/ADSOL Red Cell Preservation Solution System (PL 2209), CPD/ADSOL Red Cell Preservation Solution System (PL 2209)Morus alba root bark
go.drugbank.com/drugs/DB14271InvestigationalMorus alba root bark is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Synonyms: Sang Bai PiMagnolia kobus flowering top
go.drugbank.com/drugs/DB14319InvestigationalMagnolia kobus flowering top is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Zanthoxylum clava-herculis bark
go.drugbank.com/drugs/DB14379ExperimentalZanthoxylum clava-herculis bark is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Sulfadimethoxine
go.drugbank.com/drugs/DB06150ApprovedVet approvedWithdrawnIt is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies.
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsSynonyms: 2,6-dimethoxy-4-(p-aminobenzenesulfonamido)pyrimidineGlycyrrhizic acid
go.drugbank.com/drugs/DB13751ApprovedInvestigational[F80] It was approved by Health Canada to be used in over-the-counter products but all the products are currently on the status canceled post marketed.[L1113]
Larotrectinib
go.drugbank.com/drugs/DB14723ApprovedInvestigationalIt was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847]. On April 10, 2025, the FDA granted full drug approval.[L52805] … Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates